Qiagen (QGEN) Competitors

Qiagen (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.

Is QGEN or RGEN more profitable?

Repligen has a net margin of 21.58% compared to Qiagen's net margin of 17.66%. Qiagen's return on equity of 14.08% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	17.66%	14.08%	7.61%
Repligen	21.58%	9.14%	6.87%

Do institutionals & insiders hold more shares of QGEN or RGEN?

58.6% of Qiagen shares are owned by institutional investors. Comparatively, 91.0% of Repligen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 1.1% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media refer more to QGEN or RGEN?

In the previous week, Qiagen and Qiagen both had 4 articles in the media. Repligen's average media sentiment score of 0.80 beat Qiagen's score of 0.24 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Repligen	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, QGEN or RGEN?

Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.14 billion	4.80	$423.21 million	$1.54	29.32
Repligen	$801.54 million	11.66	$185.96 million	$2.95	56.92

Does the MarketBeat Community favor QGEN or RGEN?

Repligen received 154 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.07% of users gave Repligen an outperform vote while only 60.78% of users gave Qiagen an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 234 60.78%	Underperform Votes 151 39.22%
Repligen	Outperform Votes 388 68.07%	Underperform Votes 182 31.93%

Do analysts prefer QGEN or RGEN?

Qiagen presently has a consensus target price of $54.87, indicating a potential upside of 21.49%. Repligen has a consensus target price of $208.56, indicating a potential upside of 24.20%. Given Repligen's stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Repligen	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has more volatility & risk, QGEN or RGEN?

Qiagen has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Summary

Repligen beats Qiagen on 12 of the 17 factors compared between the two stocks.